$KPTI
Karyopharm Therapeutics Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023057754 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $33.75M $36.01M $36.15M
YoY Change 0.5% -0.38% -4.1%
Cost Of Revenue $1.486M $900.0K $980.0K
YoY Change -20.45% -8.16% 66.38%
Gross Profit $32.26M $35.10M $35.17M
YoY Change 1.73% -0.18% -5.22%
Gross Profit Margin 95.6% 97.48% 97.29%
Selling, General & Admin $30.69M $30.81M $34.65M
YoY Change -11.43% -11.08% -1.31%
% of Gross Profit 95.12% 87.76% 98.52%
Research & Development $39.38M $35.55M $31.36M
YoY Change 27.31% 13.37% -31.54%
% of Gross Profit 122.07% 101.29% 89.18%
Depreciation & Amortization $77.00K $80.00K $182.0K
YoY Change -31.86% -56.04% -2.15%
% of Gross Profit 0.24% 0.23% 0.52%
Operating Expenses $70.07M $67.27M $66.00M
YoY Change 6.84% 1.92% -19.01%
Operating Profit -$37.81M -$31.26M -$30.84M
YoY Change 11.63% 1.37% -29.61%
Interest Expense -$3.688M $6.073M -$5.456M
YoY Change -18.96% -211.31% -168.11%
% of Operating Profit
Other Income/Expense, Net -$211.0K -$3.234M $16.00K
YoY Change 1523.08% -20312.5% -100.2%
Pretax Income -$41.71M -$34.49M -$36.28M
YoY Change 8.52% -4.92% -29.84%
Income Tax $130.0K $12.00K $45.00K
% Of Pretax Income
Net Earnings -$41.84M -$34.51M -$36.32M
YoY Change 8.65% -5.0% -29.89%
Net Earnings / Revenue -123.97% -95.83% -100.5%
Basic Earnings Per Share -$0.30 -$0.45
Diluted Earnings Per Share -$0.36 -$0.30 -$452.9K
COMMON SHARES
Basic Shares Outstanding 114.5M 114.4M 79.81M
Diluted Shares Outstanding 114.4M 80.21M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $191.4M $208.3M $148.4M
YoY Change -31.13% 40.39% -27.34%
Cash & Equivalents $52.23M $43.66M $71.35M
Short-Term Investments $139.2M $164.7M $77.03M
Other Short-Term Assets $12.47M $13.80M $42.60M
YoY Change -40.28% -67.61% 190.36%
Inventory $3.043M $3.105M $4.249M
Prepaid Expenses
Receivables $26.96M $37.90M $27.45M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $233.9M $263.2M $222.7M
YoY Change -33.2% 18.21% -7.82%
LONG-TERM ASSETS
Property, Plant & Equipment $606.0K $686.0K $7.933M
YoY Change -46.8% -91.35% 404.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.635M $1.300M $626.0K
YoY Change 158.29% 107.67% -2.03%
Total Long-Term Assets $6.517M $6.738M $8.559M
YoY Change -18.64% -21.28% -31.61%
TOTAL ASSETS
Total Short-Term Assets $233.9M $263.2M $222.7M
Total Long-Term Assets $6.517M $6.738M $8.559M
Total Assets $240.4M $270.0M $231.2M
YoY Change -32.87% 16.75% -9.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.123M $943.0K $813.0K
YoY Change 12.62% 15.99% -7.72%
Accrued Expenses $61.39M $55.71M $58.49M
YoY Change 5.1% -4.74% -9.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $69.48M $62.08M $61.76M
YoY Change 5.42% 0.51% -10.32%
LONG-TERM LIABILITIES
Long-Term Debt $303.4M $303.2M $302.9M
YoY Change 0.19% 0.1% 0.44%
Other Long-Term Liabilities $978.0K $1.428M $6.863M
YoY Change -83.96% -79.19% -28.76%
Total Long-Term Liabilities $978.0K $1.428M $309.8M
YoY Change -99.68% -99.54% -0.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.48M $62.08M $61.76M
Total Long-Term Liabilities $978.0K $1.428M $309.8M
Total Liabilities $376.6M $370.4M $371.5M
YoY Change 0.48% -0.31% -2.25%
SHAREHOLDERS EQUITY
Retained Earnings -$1.500B -$1.445B
YoY Change 15.38%
Common Stock $1.351B $1.346B
YoY Change 1.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$136.2M -$100.4M -$140.3M
YoY Change
Total Liabilities & Shareholders Equity $240.4M $270.0M $231.2M
YoY Change -32.87% 16.75% -9.0%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$41.84M -$34.51M -$36.32M
YoY Change 8.65% -5.0% -29.89%
Depreciation, Depletion And Amortization $77.00K $80.00K $182.0K
YoY Change -31.86% -56.04% -2.15%
Cash From Operating Activities -$18.58M -$29.53M -$28.37M
YoY Change -30.76% 4.09% 18.43%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$39.00K
YoY Change -100.0% 680.0%
Acquisitions
YoY Change
Other Investing Activities $26.84M -$7.680M $11.71M
YoY Change -141.11% -165.57% -45.35%
Cash From Investing Activities $26.84M -$7.680M $11.67M
YoY Change -141.11% -165.79% -45.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 264.0K 0.000 5.799M
YoY Change -99.83% -100.0% 36143.75%
NET CHANGE
Cash From Operating Activities -18.58M -29.53M -28.37M
Cash From Investing Activities 26.84M -7.680M 11.67M
Cash From Financing Activities 264.0K 0.000 5.799M
Net Change In Cash 8.522M -37.21M -10.90M
YoY Change -86.62% 241.44% 333.66%
FREE CASH FLOW
Cash From Operating Activities -$18.58M -$29.53M -$28.37M
Capital Expenditures $0.00 $0.00 -$39.00K
Free Cash Flow -$18.58M -$29.53M -$28.33M
YoY Change -30.76% 4.23% 18.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36167
dei Entity Registrant Name
EntityRegistrantName
Karyopharm Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
658-0600
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
KPTI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114533991
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43655000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135188000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
164660000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
142779000
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
37923000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
47086000
CY2023Q3 us-gaap Inventory Net
InventoryNet
3105000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13334000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19821000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
545000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1064000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
263222000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
350162000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
686000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1139000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4796000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6238000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
381000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
633000
CY2023Q3 us-gaap Other Assets
OtherAssets
875000
CY2022Q4 us-gaap Other Assets
OtherAssets
0
CY2023Q3 us-gaap Assets
Assets
269960000
CY2022Q4 us-gaap Assets
Assets
358172000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
943000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2773000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55713000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58415000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3195000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2872000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2228000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1848000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
62079000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65908000
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170702000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170105000
CY2023Q3 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132479000
CY2022Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132718000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3668000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6097000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1428000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q3 us-gaap Liabilities
Liabilities
370356000
CY2022Q4 us-gaap Liabilities
Liabilities
374828000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114523000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114523000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113213000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113213000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1345535000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1327909000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-742000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-638000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1445201000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1343939000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-100396000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269960000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
358172000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36009000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36145000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
112286000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
123494000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35553000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31359000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
99369000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
117730000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30805000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34645000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
101193000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
110752000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
67269000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
66984000
us-gaap Operating Expenses
OperatingExpenses
204018000
us-gaap Operating Expenses
OperatingExpenses
231827000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31260000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30839000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91732000
us-gaap Operating Income Loss
OperatingIncomeLoss
-108333000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2750000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
658000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8423000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1025000
CY2023Q3 us-gaap Interest Expense
InterestExpense
6073000
CY2022Q3 us-gaap Interest Expense
InterestExpense
6114000
us-gaap Interest Expense
InterestExpense
17615000
us-gaap Interest Expense
InterestExpense
19111000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
89000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-145000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3234000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5440000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9337000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18156000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34494000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36279000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101069000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-126489000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
45000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
193000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
296000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-36324000
us-gaap Net Income Loss
NetIncomeLoss
-101262000
us-gaap Net Income Loss
NetIncomeLoss
-126785000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.60
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114401000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114401000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80210000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80210000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114033000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114033000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79153000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79153000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-36324000
us-gaap Net Income Loss
NetIncomeLoss
-101262000
us-gaap Net Income Loss
NetIncomeLoss
-126785000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
169000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-145000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-95000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-329000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-128000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-69000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-614000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34465000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36538000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101366000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127728000
us-gaap Profit Loss
ProfitLoss
-101262000
us-gaap Profit Loss
ProfitLoss
-126785000
us-gaap Share Based Compensation
ShareBasedCompensation
16527000
us-gaap Share Based Compensation
ShareBasedCompensation
29226000
us-gaap Depreciation
Depreciation
453000
us-gaap Depreciation
Depreciation
508000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
597000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
602000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3077000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
361000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9163000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4949000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1119000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
143000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5612000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7977000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1442000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1234000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1830000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-790000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-779000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-11621000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2106000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1652000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74138000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-122711000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
123688000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
90078000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
142591000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
128918000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18903000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38958000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
0
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
35082000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
860000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2813000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
860000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37895000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-123000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-614000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-92304000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-124388000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44581000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73057000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43655000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71351000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
545000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1080000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
381000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
626000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44581000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73057000
us-gaap Interest Paid Net
InterestPaidNet
2588000
us-gaap Interest Paid Net
InterestPaidNet
2588000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
2770000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
2523000
us-gaap Payments For Royalties
PaymentsForRoyalties
12225000
us-gaap Payments For Royalties
PaymentsForRoyalties
24960000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-71248000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5078000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
239000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
169000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-128000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-100396000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-116338000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6797000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5788000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-145000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-69000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-36324000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-140280000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
860000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16527000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
239000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-95000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000
us-gaap Net Income Loss
NetIncomeLoss
-101262000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-100396000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2813000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29226000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35082000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-329000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-614000
us-gaap Net Income Loss
NetIncomeLoss
-126785000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-140280000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
165102000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
443000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
391000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1370000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1955000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1878000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
759000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
976000
CY2023Q3 us-gaap Inventory Net
InventoryNet
3105000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2023Q3 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
5802000
CY2022Q3 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
4136000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
25331000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
34175000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
196448000
CY2023Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
265906000
CY2022Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
164660000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
143123000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
348000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
142779000
CY2023Q3 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2023Q3 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
74
CY2022Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
60
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
152062000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
425000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
3787000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
18000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
155849000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
443000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
348000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
348000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5078000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6797000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16527000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29226000
kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five-business day period immediately after any five consecutive trading day period
us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98
kpti Second Investment Amount
SecondInvestmentAmount
60000000
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-057754-index-headers.html Edgar Link pending
0000950170-23-057754-index.html Edgar Link pending
0000950170-23-057754.txt Edgar Link pending
0000950170-23-057754-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20230930.htm Edgar Link pending
kpti-20230930.xsd Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
kpti-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
kpti-20230930_cal.xml Edgar Link unprocessable
kpti-20230930_pre.xml Edgar Link unprocessable
kpti-20230930_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
kpti-20230930_def.xml Edgar Link unprocessable
kpti-20230930_lab.xml Edgar Link unprocessable